Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

Cancer Chemotherapy and Pharmacology

Volumn 32, Issue 3, 1993, Pages 167-172

  Shirasaka, Tetsuhiko ^a   Shimamoto, Yuji ^a   Ohshimo, Hideyuki ^a   Saito, Hiroko ^a   Fukushima, Masakazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLIC ACID; METHYLENETETRAHYDROFOLIC ACID; UFT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR CELL;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CISPLATIN; DRUG SYNERGISM; FLUOROURACIL; FOLIC ACID; LEUKEMIA P388; MALE; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OXIDATION-REDUCTION; RATS; RATS, INBRED STRAINS; SARCOMA, YOSHIDA; TUMOR CELLS, CULTURED;

EID: 0027285520     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685830     Document Type: Article

References (41)

1. Differentiation of DNA-platinum complexes by fluorescence. The use of an intercalating dye as a probe
2. Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer
3. Continuous infusion or bolus injection in cancer chemotherapy
4. Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver
5. Continuous infusion 5-fluorouracil and weekly low dose cisplatin in metastatic gastrointestinal malignancies
6. The synthesis of 5-fluoropyrimidines
7. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
8. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcoma in rats
9. Phase II trial of carboplatin and tegaful (ftorafur) as induction therapy in squamous-cell carcinoma of the head and neck
10. Phase II trial of cisplatin and tegaful (ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck
11. Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin
12. Studies on fluorinated pyrimidines: XII. Inhibition of thymidylate synthase
13. Infusional high dose cis-platinum and 5-fluorouracil in advanced non-small cell lung cancer: a Mid-Atlantic Oncology Program pilot study
14. Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
15. Activity of 96 hour to 120 hour 5-fluorouracil infusion in advanced and recurrent head and neck cancer
16. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer
17. The regulation of folate and methionine metabolism
18. Thymidylate synthase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate
19. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study
20. Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma
21. Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma
22. Pyrimidine nucleosides enhance the anticancer activity of FU and augment its incorporation into nuclear RNA
23. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice
24. Effects of 5-fluorouracil and cis-DDP combination on human colorectal tumor xenografts
25. Comparison of folylpolyglutamate hydrolase of mouse liver, kidney, muscle and brain
26. Resultants d'une etude de phase II d'une association de cis-platinum et de 5-FU les cancers bronchiques epidermoides on indifferencies a grades cellules
27. Improved complete response rates and survival in advanced head and neck cancer after three-course induction therapy with 120 hours 5-FU infusion and cisplatin
28. 5-Fluoro-2′-deoxyuridylate: covalent complex with thymidylate synthase
29. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells
30. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
31. Phosphorous compounds in animal tissues: III. Comparison of methods for the estimation of nucleic acids
32. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
33. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and-resistant murine colon adenocarcinomas
34. Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil
35. Mechanism of innate resistance to thymidylate synthase inhibition after 5-fluorouracil
36. The clinical effects of continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxyuridine)
37. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
38. Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy
39. Superior clinical response and survival rates with initial bolus cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer
40. Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer
41. The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine